Mirum Pharmaceuticals, Inc. (MIRM) Tops Q3 EPS by 15c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Mirum Pharamceuticals (MIRM) PT Raised to $70 at Stifel
November 12, 2024 12:51 PM ESTStifel analyst Dae Gon Ha raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $70.00 (from $66.00) while maintaining a Buy rating.
The analyst comments "Commercial progress (Livmarli, Chenodal, Cholbam) is on a positive trajectory as implied by $90.3M in product revenue with guidance... More
